Valuation: Black Diamond Therapeutics, Inc.

Market Cap 11Cr 9.26Cr 8.52Cr 7.94Cr 15Cr 1TCr 15Cr 102.49Cr 40Cr 492.04Cr 40Cr 39Cr 1.71TCr P/E 2026 *
-2.84x
P/E 2027 * -1.83x
Enterprise Value 11Cr 9.26Cr 8.52Cr 7.94Cr 15Cr 1TCr 15Cr 102.49Cr 40Cr 492.04Cr 40Cr 39Cr 1.71TCr EV / Sales 2026 *
19x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day+5.71%
1 week+15.00%
Current month+5.68%
1 month-10.32%
3 months-18.20%
6 months-21.49%
Current year-19.55%
1 week 1.68
Extreme 1.68
2.02
1 month 1.6
Extreme 1.6
2.21
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
12.1
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 50 01/12/2018
Date Insider Type Main position Quantity % Market Cap.
26/06Free

Director

40,000 0.0698%
26/06Free

Director

40,000 0.0698%
26/06Free

Director

40,000 0.0698%
Change 5-day change 1-year change 3-year change Capi.($)
+5.71%+15.00%-24.81%-58.32% 11Cr
+4.51%+6.19%+77.47%+137.61% 5.62TCr
+0.55%+8.49%+77.09%+100.93% 5.54TCr
+3.95%+8.93%-9.44%-9.07% 2.38TCr
+2.77%+6.31%+13.05%+435.23% 2.32TCr
+3.64%+10.54%+39.81%-4.50% 1.81TCr
+4.11%+8.92%+44.64%-27.71% 1.68TCr
+2.57%+20.26%+181.98%+355.99% 1.59TCr
+3.35%+5.43%+26.68%+193.36% 1.36TCr
+7.20%+10.70%+42.91% - 1.3TCr
Average +3.86%+6.83%+46.94%+124.84% 2.36TCr
Weighted average by Cap. +3.25%+7.07%+59.22%+138.61%

Financials

2026 *2027 *
Net sales 55.56L 48.78L 44.9L 41.84L 78.9L 53Cr 80.51L 5.4Cr 2.09Cr 26Cr 2.09Cr 2.04Cr 90Cr -
Net income -4.05Cr -3.55Cr -3.27Cr -3.05Cr -5.75Cr -384.79Cr -5.86Cr -39Cr -15Cr -188.88Cr -15Cr -15Cr -657.34Cr -7Cr -6.15Cr -5.66Cr -5.27Cr -9.95Cr -665.94Cr -10Cr -68Cr -26Cr -326.88Cr -26Cr -26Cr -1.14TCr
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
02/26/02 $1.950 +5.98% 5,15,547
01/26/01 $1.840 -0.54% 43,75,137
30/26/30 $1.850 +5.71% 18,83,436
29/26/29 $1.750 +2.34% 11,54,453
26/26/26 $1.710 +0.59% 85,78,830
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.840USD
Average target price
9.857USD
Spread / Average Target
+435.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock